Steglatro (Ertugliflozin Pidolate) Patent Expiration, LOE Window & CMS Spending
Steglatro (Ertugliflozin Pidolate) by Merck & Co.: FDA Orange Book core substance LOE 2031-12-19, 0 AB generics, $125.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Merck & Co. |
| FDA Application & Pathway | N209803 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-12-19 |
| Last Listed Patent or Exclusivity Date | 2031-12-19 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $125.1M |
| 2024 Medicare Part D Spend | $16.5M |
| 2024 Medicaid Spend | $108.5M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.